A non-exclusive voluntary licensing agreement has been signed by the Pakistani pharmaceutical business Ferozsons Laboratories Limited (Ferozsons) and the US biopharmaceutical company Gilead Sciences Ireland UC for the production and distribution of licensed generic lenacapavir.
The Pakistan Stock Exchange (PSX) received a note from the listed business on Thursday informing them of the situation.
Ferozsons has disclosed that it is among the six international partners that have agreed to a voluntary license with Gilead for the production of superior lenacapavir generics.
According to the business, lenacapavir is being looked at for use in HIV prevention and has been licensed by the US FDA [Food and Drug Administration] for treatment-experienced patients (HTE) with HIV infection.
The agreement includes the authorized indication of HIV therapy in severely treatment-experienced (HTE) people with multi-drug resistant HIV, as well as lenacapavir for HIV prophylaxis (pending approval).
The business stated that lenacapavir’s safety and effectiveness for HIV prevention are still being investigated and have not been proven.
Ferozsons or its affiliates may produce and market their licensed generic version of Gilead’s proprietary compound Lenacapavir in 120 (one hundred twenty) countries, mostly low- and lower-middle-income nations, provided that the necessary regulatory licenses are obtained. This is a non-exclusive license.
The statement added, “The business has a right to get a technology transfers of the Gilead manufacturing method for lenacapavir under the licensing agreement so that it can scale up production.”
Lenacapavir, according to Ferozsons, comes in two dose forms: (a) an injectable medication in the form of a vial kit that contains 309 mg/mL of the medicine, or (b) an oral medication that contains 300 mg of the substance.
